Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Thursday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX opened at $1.30 on Thursday. The company’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.47. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.37.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Eagle Pharmaceuticals during the third quarter valued at approximately $96,000. DGS Capital Management LLC increased its position in Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Eagle Pharmaceuticals during the third quarter worth approximately $453,000. Finally, RBF Capital LLC increased its position in Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.